A comprehensive portal site for Medical Innovation Support Office (MEDISO).Medical Innovation Support Office

Tomohiko Goto

TAIYO Pharma Co.,Ltd CMC Solutions Dept. Manager

Having extensive experience and achievements in formulation development, new drug application processes, investigational drug formulation development, support for overseas clinical trials, plant construction and GMP acquisition through long years at a pharmaceutical company, and more recently, engaging in CMC activities for investigational drug development and clinical trial advancement at a medical bio-venture company within Shonan i-Park(Kanagawa,Japan), I hope to contribute as a part-time CMC supporter for MEDISO. I am passionate about supporting the swift delivery of unmet need pharmaceuticals developed by domestic and international medical pharmaceutical venture companies to patients. Among many support areas, if I can contribute my specialized and niche knowledge in the CMC field (particularly in formulation development) to address challenges in cutting-edge bio-venture research worldwide through the MEDISO project, and support quicker entry into clinical trials, it would be most gratifying.

Hirohumi Shido

I am a UI/UX design expert and specialize in driving product development. As a product manager at a medical startup, he was in charge of renewal and new planning for multiple SaMD products. My experience ranges from planning to obtaining regulatory approval, and I have won a Good Design Award for a healthcare product. These experiences have made me realize the importance of experience design and usability in SaMD products with a diverse mix of stakeholders.

Teppei Konishi

Biomy Inc. CEO

He completed his graduate studies at the Graduate School of Engineering Science, Osaka University. At NTT DOCOMO, he specialized in big data analysis and AI-driven video analysis research, contributing to new business development. After leaving NTT DOCOMO, he served as CTO at an IT venture before founding Biomy Co., Ltd. There, he led the development of a personalized medical platform utilizing AI technology, collaborating with domestic and international pharmaceutical companies and research institutions. He also secured a Class II medical device manufacturing and sales license.

Kazuhiro Takekita

Osaka University Graduate School of Medicine, Department of Vascular Regeneration and Podiatry, Associate Professor

He was involved in launching a project of regenerative medicine by using autologous skeletal muscle-derived cell sheets in the Department of Cardiovascular Surgery, Graduate School of Medicine, Osaka University. Subsequently, he was involved in the evaluation of regenerative and biological devices at the Pharmaceuticals and Medical Devices Agency (PMDA). He performed several duties related to the Health Labour Sciences Research Grant, clinical study of human stem cells, and advanced medical care at the Research and Development Division, Health Policy Bureau, Ministry of Health, Labour and Welfare. After that, he led the regenerative medical product evaluation unit as chief of the Office of Review for Regenerative Medical Product, PMDA. Also, he was involved in improving the legislation for regenerative medical products in the revision of the Pharmaceutical Affairs Law in 2014. From August 2017, he has been serving as a specially appointed lecturer in the Department of Cardiovascular Surgery, Graduate School of Medicine, Osaka University, where he promotes projects to develop various products derived from human-induced pluripotent stem cells.

Shinichi Watanabe

WNW IP ATTORNEYS

Shinichi Watanabe began his career as a patent attorney in 2003, and with the valuable experience gained at global patent law firms. His practice primarily deals with filing and prosecution of domestic and international patent applications in the pharmaceutical and biotechnology fields. Backed up by a wealth of practical experience and technical expertise, he is actively engaged in IP counselling and advises start-up pharmaceutical and biotech companies on patent filing strategies. Recently, he is interested in AI and machine learning, and now also working on support in the interdisciplinary area between life science, IT and AI.